# Research Peptide Fundamentals: Why Peptides Are Injected, and What Survives Being Swallowed > Natural Oral Peptides — Research Peptide Fundamentals: The Absorption Problem — Why Research Peptide Fundamentals starts with absorption: what the stomach does to research peptides, why almost all of them are injected, and the one engineered tablet that gets through. **ABSORPTION / RESEARCH PEPTIDE FUNDAMENTALS** A blunt reading of the absorption problem. What the gut does to a peptide, why the needle is a chemistry decision rather than a preference, and the single heavily engineered tablet that beat the odds. ### [BPC-157](/bpc-157) ![BPC-157 research illustration](images/bpc-157.webp) Named for the gastric juice its parent protein was found in, and sold in capsules and sprays on the strength of that name. The only formal human pharmacokinetic work used a needle, and the one published route comparison went the same way. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) The exception that defines the rule. A GLP-1 analogue engineered hard enough to survive a stomach and approved as a daily tablet as well as a weekly injection, while still delivering only a small fraction of the swallowed material to the blood. ### [NAD+](/nad) ![NAD+ research illustration](images/nad.webp) Not a peptide at all, which is exactly why it is here. An endogenous coenzyme whose oral precursors genuinely raise blood levels in controlled trials, and a clean picture of what real oral availability looks like when the molecule is small enough. ## The short version Peptides are short chains of amino acids, the same building blocks that make up the protein in food. That is the whole problem. The digestive system exists to take protein apart, and it does not check whether a particular chain was meant as a signal or as a meal. Stomach acid unfolds it. Protein-cutting enzymes called proteases cut it into fragments. Whatever survives still has to cross an intestinal wall built to keep molecules of that size out. Very little gets through, which is why almost every research peptide is studied as an injection. The needle is not a preference and not a marketing choice. It is what the chemistry leaves. This site is about the narrow set of exceptions: one approved tablet that took serious engineering to build, one endogenous coenzyme that is not a peptide at all, and one widely sold compound whose oral evidence simply does not exist. ## Why the needle is a chemistry decision, not a preference Two barriers stand between a swallowed peptide and the bloodstream, and they are independent of each other. Clearing one does nothing about the other. The first is proteolysis. Acid in the stomach denatures the peptide, pepsin begins cutting it, and pancreatic enzymes released into the small intestine continue the work. Peptidases anchored in the intestinal lining break down much of what is left at the last moment before absorption. The endpoint of that breakdown is ordinary nutrition rather than a damaged drug: the formal pharmacokinetic work on BPC-157 found the peptide breaking down rapidly into small fragments that enter normal amino-acid metabolism [3]. A peptide that loses this fight does not become a weaker drug. It becomes lunch. The second is permeability. The cells lining the intestine are sealed to each other by tight junctions, and a peptide is both large and water-loving, which is close to the worst combination for crossing a lipid membrane. Passive diffusion through those cells is poor, and the route between them is effectively closed. Anything that clears both barriers then meets the liver before it reaches the general circulation. For an unmodified peptide the result is an oral bioavailability that rounds to nothing. Every engineering trick used to build an oral peptide is aimed at one or both of those barriers, and none of them removes a barrier. They reduce the loss. ## What the word natural does not buy a molecule Natural is a marketing word. Pharmacologically it carries almost no information, and on a page about oral peptides it is close to actively misleading. Endogenous origin says nothing about oral viability. NAD+ is manufactured by every living cell in the body, and swallowed NAD+ is still poorly taken up intact, which is why the human trials on this site use precursors rather than the coenzyme itself. BPC-157 is derived from a partial sequence of a protein identified in human gastric juice, and its research designation calls it a stable gastric pentadecapeptide. Stability in gastric juice is a narrower claim than absorption across the gut wall, and the two get blurred routinely in product copy. Run the argument the other way and it collapses faster. The most heavily engineered molecule on this site is the only one with an approved oral form: a GLP-1 analogue carrying a non-natural amino acid at one position, a swapped residue at another, and a fatty di-acid chain bolted on to bind albumin. Whatever lets a peptide survive a stomach, it is not naturalness. It is chemistry that nature did not supply. Natural carries no safety guarantee either. BPC-157 is not approved as a medicine anywhere, moves through non-regulated channels where identity, purity and actual content go unverified, and a 2025 review treats it as investigational for exactly those reasons [2]. ## What oral means here, and what it does not Three different things are sold under the same word, and only two of them have controlled human data behind the route. The first is an approved oral tablet designed around an absorption enhancer and taken under a strict fasting rule. Oral semaglutide is the flagship case and, at present, close to the entire category. The second is a capsule, troche or sublingual spray of a peptide with no published human oral pharmacokinetic study behind it. BPC-157 is the example on this site. The absence is the finding. Nothing gathered here demonstrates that such a product delivers a meaningful quantity to the bloodstream, and nothing gathered here demonstrates that it delivers none. The third is a small-molecule precursor of an endogenous metabolite, which is not a peptide at all. Oral NMN and oral NR raise blood NAD+ in controlled trials [14][17]. That is real oral bioavailability, and it belongs to nucleotide chemistry rather than to peptide chemistry. This digest describes no product, endorses no delivery format and recommends nothing to anyone. Where the oral evidence does not exist, the page says so rather than filling the gap with a mechanism story. ## What a research peptide is, and what these three actually are A peptide is a short chain of amino acids, shorter than a protein and long enough to act as a signalling molecule. The word describes a size class, not a legal status, and the three compounds gathered here sit at three completely different points on that scale. Semaglutide is an approved prescription medicine with an outcome-trial record running to tens of thousands of participants [10][11]. BPC-157 is not approved as a medicine anywhere, is sold for laboratory research use only, and rests on a human evidence base of a handful of small pilot reports [2]. NAD+ is neither of those things: an endogenous coenzyme sold as a dietary supplement, present on this site as a control case rather than as a peer. Grouping all three under the word peptide hides every one of those distinctions, and that grouping is what a great deal of product copy relies on. Sorting them by route, and by the state of the evidence behind that route, is more useful. That is what the comparison page does. --- An independent reading desk on what survives the trip from mouth to bloodstream, selling nothing, prescribing nothing and endorsing no capsule, spray or protocol.